Tissue origin | % Cases with +HA staining |
Breast | Tumour (N=117, 56%) |
Normal (N=13, 23%) | |
Prostate | Tumour (N=110, 46%) |
Normal (N=17, 5.8%) | |
Bladder | Tumour (TCC) (N=106, 43%) |
Normal (N=8, 0%) | |
Stomach | Tumour (adenocarcinoma) (N=95, 42%) |
Normal (N=14, 0%) | |
Pleura | Tumour (mesothelioma) (N=52, 37%) |
Normal (N=15, 0%) | |
Lung | NSCLC (N=169, 29%) |
SCLC (N=21, 10%) | |
Normal (N=21, 0%) | |
Ovary | Tumour (N=185, 12%) |
Normal (N=31, 0%) | |
Colon | Tumour (N=136, 28%) |
Normal (N=25, 8%) | |
Bone marrow | Multiple myeloma (N=27, 3.7%) |
Normal (N=35, 0%) | |
Pancreas | Ductal adenocarcinoma (N=99, 90%) |
Acinar cell carcinoma (N=2, 0%) | |
Mucinous adenocarcinoma (N=5, 100%) | |
Papillary adenocarcinoma (N=4, 25%) | |
Squamous cell carcinoma (N=2, 100%) | |
Normal (N=25, 4%) |
HA staining is most common in pancreatic ductal adenocarcinoma in comparison to other major human tumours.
HA, hyaluronan. TMA, tissue microarray. TCC, transitional cell carcinoma. NSCLC, non-small cell lung carcinoma. SCLC, small cell lung carcinoma.